Perth life-sciences company Proteomics has received a US patent for its PromarkerEndo blood test and is moving to expand testing capacity across Australia as it aims for a commercial launch in 2027.
The patent covers PromarkerEndo, a diagnostic intended to identify endometriosis from blood samples. The intellectual property milestone comes as the company shifts from research and development toward broader availability of its testing technology nationwide.
Alongside the patent news, Proteomics has initiated a corporate restructure that has resulted in redundancies. The company says the changes form part of preparations to scale the business and support a national roll-out of blood testing services.
Proteomics’ plans mark a significant development for a WA-based biotech seeking to take a laboratory test from clinical development to routine clinical use across Australia. The move will require operational expansion, including laboratory capacity, logistics and clinician engagement, to deliver testing more widely.
If deployed at scale, a blood-based diagnostic for endometriosis could change how the condition is assessed in primary and specialist care, potentially reducing reliance on invasive procedures. Providers and patients would be likely stakeholders in any transition to routine blood testing.
The company’s next steps will include commercialisation activities. That pathway typically involves establishing regulatory clearances, forging distribution and referral arrangements with clinicians and pathology providers, and securing payor arrangements, although Proteomics has not publicly detailed those specific milestones.
The restructure and staff reductions underscore the tensions that can accompany the shift from research-led operations to a commercial business model. For Proteomics, aligning costs and capabilities ahead of a broader market launch appears to be the immediate priority.
Regional impact is focused in Western Australia, where Proteomics is headquartered, but the planned national rollout means the company’s activities and any resulting patient access changes would reverberate across Australia’s healthcare system.
For investors and partners watching the sector, the US patent provides a stronger intellectual property position for PromarkerEndo. Commercial success will depend on execution of the rollout, regulatory and reimbursement pathways, and clinician uptake.
Proteomics’ timeline of targeting a 2027 launch gives the market a clear milestone to monitor. In the interim, observers should expect further announcements on regulatory status, commercial partnerships and operational expansion as the company transitions to wider availability of its test.
Overall, the patent grant is a key technical and legal achievement for Proteomics, while the ongoing restructure signals the practical and financial adjustments the company is making to prepare for a move into national diagnostic services.
